Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol dosing regimens in CKD Stage 5 hemodialysis
NCT01071070Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2009
- Primary completion
- Nov 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by Abbott Laboratories. Started Nov 2009; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01071070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071070.